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Abstract
Background: Drug resistance hampers the efficient treatment of malignancies, including advanced stage ovarian
cancer, which has a 5-year survival rate of only 30 %. The molecular processes underlying resistance have been
extensively studied, however, not much is known about the involvement of microRNAs.
Methods: Differentially expressed microRNAs between cisplatin sensitive and resistant cancer cell line pairs were
determined using microarrays. Mimics were used to study the role of microRNAs in drug sensitivity of ovarian
cancer cell lines and patient derived tumor cells. Luciferase reporter constructs were used to establish regulation of
target genes by microRNAs.
Results: MiR-634 downregulation was associated with cisplatin resistance. Overexpression of miR-634 affected cell
cycle progression and enhanced apoptosis in ovarian cancer cells. miR-634 resensitized resistant ovarian cancer cell
lines and patient derived drug resistant tumor cells to cisplatin. Similarly, miR-634 enhanced the response to
carboplatin and doxorubicin, but not to paclitaxel. The cell cycle regulator CCND1, and Ras-MAPK pathway
components GRB2, ERK2 and RSK2 were directly repressed by miR-634 overexpression. Repression of the Ras-MAPK
pathway using a MEK inhibitor phenocopied the miR-634 effects on viability and chemosensitivity.
Conclusion: miR-634 levels determine chemosensitivity in ovarian cancer cells. We identify miR-634 as a therapeutic
candidate to resensitize chemotherapy resistant ovarian tumors.
Keywords: microRNA, miRNA, Drug resistance, miR-634, Ras-MAPK pathway, Ovarian cancer, Chemotherapy,
Cisplatin, RPS6KA3, RSK2
Background
Ovarian tumors are a group of molecularly and etio-
logically heterogeneous cancers [1], and are the fifth
most common cause of cancer related mortality among
women. The current standard of therapy is debulking
surgery and combination chemotherapy, consisting of a
taxane (e.g. paclitaxel) and a platinum-based compound
(e.g cisplatin or carboplatin) [2, 3]. Despite an initial
high chemo-responsiveness, with response rates over
80 % [4], most advanced epithelial ovarian cancer
patients will relapse and ultimately die of drug-resistant
disease [5].
In the cellular response to cytotoxic substances, cell
signaling pathways, such as the MAPK pathways, play a
pivotal role. The classical MAPK pathway is activated by
receptor tyrosine kinases (RTK), which bind GRB2 and
SOS, after which the kinases RAS, RAF, MEK and
MAPK are sequentially activated. Three major MAPK
routes have been identified: the p38 MAPK, Jun kinase
and ERK pathway. The MAPK pathways regulate nu-
merous targets, including p90 ribosomal S6 protein
kinases (RSKs), which in turn can activate downstream
proteins. Together, MAPK pathways regulate the activity
of genes involved in cell proliferation, DNA damage
repair, cell cycle progression and apoptosis [6–10].
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Although the mechanisms behind chemotherapy re-
sistance in ovarian cancer have been studied extensively,
the involvement of microRNAs (miRNAs), small RNAs
that regulate gene expression, is just beginning to be un-
raveled [11, 12]. We have recently shown that miR-141
targets KEAP1 in ovarian cancer cells, repression of
which results in enhanced cisplatin resistance [13]. In
the current study we aimed to identify additional miR-
NAs that play a role in cisplatin resistance. Here, we de-
scribe that miR-634 can sensitize both ovarian cancer
cell lines and primary ovarian cancer cell cultures to
chemotherapy. We show that miR-634 regulates cyclin
D1 and several Ras-MAPK pathway components (GRB2,
ERK2, RSK1 and RSK2), which may contribute to the ef-
fects of miR-634 on ovarian cancer cell survival and
chemotherapy response.
Results
Comparison of miRNA expression profiles of cisplatin
sensitive and resistant cell line pairs
In order to find miRNAs that play a role in cisplatin re-
sistance, we compared miRNA expression profiles of cis-
platin sensitive/resistant cell line pairs (IC50 values in
Additional file 1: Table S1A). We hypothesized that in
different cell types the same miRNAs play a role in cis-
platin sensitivity, as has been reported for other factors
involved in drug resistance [14]. Therefore, the miRNA
expression pattern of an ovarian cancer cell line pair
(A2780/A2780 DDP) was compared with expression pat-
terns of a bladder cancer (T24/T24 DDP) and colon can-
cer (HCT8/HCT8 DDP) cell line pair. The only miRNA
that showed a common pattern in all cell lines was miR-
634 (Additional file 1: Figure S1, FDR = 0.000), which
was downregulated ≥1.5 fold in all cisplatin resistant cell
lines (Additional file 1: Table S2). We further investi-
gated the role of miR-634 in ovarian cancer.
Effects of miR-634 overexpression on cell cycle and
apoptosis
Before examining the effects of miR-634 on cisplatin
sensitivity, we determined whether miR-634 overexpres-
sion affects the cell cycle and cell survival of A2780
DDP cells, which have a low basal miR-634 expression
compared to the parental A2780 cells. Upon transfection
of the miR-634 mimic, a slightly higher percentage of
cells was observed in the G1 phase (p = 0.04) accom-
panied by a lower number of cells in the G2/M phase
(p = 0.04) (Fig. 1a). These effects, which were
observed at 48 h after transfection in multiple experi-
ments, suggest that miR-634 overexpression may
affect the G1-to-S phase transition. At 72 h after
transfection, however, the cell cycle profile of miR-
634 overexpressing cells was comparable to cells
transfected with scrambled mimic (Fig. 1a).
Next, we examined if miR-634 overexpression induces
apoptosis. Whereas at 48 h after transfection the viability
of control and miR-634 mimic transfected cells was
comparable, at 72 h the percentage of viable cells was
significantly lower (p = 0.03) in miR-634 transfectants,
corresponding to increased numbers of apoptotic and
dead cells (Fig. 1b). This effect of miR-634 on apoptosis
was also detected by MTT assay in five other ovarian
cancer cell lines, A2780 (parental line), OV56, OAW42,
TOV21G and TOV112D. In these cells miR-634 gave
rise to a 20–50 % reduction in viability, relative to con-
trol transfectants (Fig. 1c).
MiR-634 enhances cisplatin sensitivity of ovarian cancer
cell lines
We next determined the effects of miR-634 overex-
pression on cisplatin sensitivity using a previously de-
veloped assay [13]. Briefly, cells were transfected with
a miR-634 mimic or a scrambled control, and after
48 h exposed to various concentrations of cisplatin.
After another 24 h cell viability was determined using
an MTT assay. Because miRNA transfection was tran-
sient we used 24 h drug exposure intervals. Note that
the difference in IC50 values observed between drug
sensitive and resistant cell lines was similar to IC50
values determined in assays with longer drug expos-
ure times [13] (Additional file 1: Table S1A, C). As is
shown in Fig. 2a, transfection with miR-634 mimic
gave rise to a marked increase in sensitivity after
treatment with 80 μM (p = 0.006) and 125 μM cis-
platin (p = 0.002) in the A2780 DDP cell line. A pos-
sible explanation for this sensitization may be a
higher intracellular cisplatin accumulation and con-
comitantly increased cytotoxic activity. In fact, cis-
platin resistance is frequently accompanied by
reduced intracellular cisplatin levels [15] (Additional
file 1: Table S1B). We measured the intracellular plat-
inum content of miR-634 and scrambled control
transfected cells after exposure to 80 and 125 μM cis-
platin for 2 h, 6 h and 12 h. MiR-634 transfection did
not affect the platinum uptake by A2780 DDP cells
(Additional file 1: Figure S2) ruling out that miR-634
sensitizes ovarian cancer cells for cisplatin by increas-
ing its uptake and/or reducing its efflux.
In contrast to the resistant A2780 DDP cell line,
enhanced expression of miR-634 in the sensitive
A2780 cells did not alter the sensitivity for cisplatin.
This might be due to the fact that miR-634 levels are
already high in A2780 cells relative to A2780 DDP.
We next examined the effect of miR-634 transfection
on other ovarian cancer cell lines. Because the most
significant effect was observed at the IC25 dose in the
A2780 DDP cell line, the other ovarian cancer cell
lines were treated with the IC25 dose of mock
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(transfection reagent only) transfected cells
(Additional file 1: Table S1C). In two of the most re-
sistant cell lines in this assay, OV56 and TOV21G,
miR-634 overexpression significantly reduced viability
(Fig. 2b). In contrast, in the more sensitive cell lines
OAW42 and TOV112D, overexpression of miR-634
did not alter sensitivity. The effect of miR-634 on
cisplatin response thus appears to be strongest in
resistant cell lines.
MiR-634 sensitizes tumor cells from patients with drug
resistant ovarian cancer to chemotherapy
Ovarian cancer is routinely treated with platinum (e.g.
cisplatin, carboplatin) and taxane (e.g. paclitaxel) based
combination chemotherapy. However, most tumors
eventually become resistant. As miR-634 overexpression
can increase cisplatin sensitivity of cell lines, we exam-
ined whether this treatment could also sensitize chemo-
therapy resistant primary ovarian tumor cells. Ascites
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Fig. 1 MiR-634 overexpression induces G1 arrest and causes cell death. a Percentage of A2780 DDP cells in G0/G1, S or G2/M phase 48 or 72 h
after transfection with a miR-634 mimic or a scrambled control (n = 3), * = p < 0.05. b A2780 DDP cells were stained with PI and Annexin V 48 or
72 h after transfection with miR-634 mimic or a scrambled control. Depicted are viable (PI/Annexin V negative), early apoptotic (Annexin V
positive/PI negative), late (Annexin V positive/PI positive) and dead (PI positive/Annexin V negative) cells (n = 3). c Viability of miR-634 mimic
transfected ovarian cancer cells compared to cells transfected with a scrambled mimic (set at 100 %), as determined by an MTT assay 72 h after
transfection. Depicted are average values ± SD (n = 3)
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was collected from 6 patients with serous and 1 patient
with clear cell ovarian cancer (for patient characteristics,
see Table 1). One patient was chemotherapy naïve, the
others had received carboplatin/paclitaxel combination
regimens and were or had become resistant. The ovarian
cancer cells were isolated and cultured from ascites as
described previously [16, 17], All cultures tested positive
for the epithelial marker pan-keratin (Additional file 1:
Figure S3). Another epithelial marker, EpCAM, was only
positive in tumor cells from patient 2, however it is
known that primary ovarian cancer cells may lose
EpCAM expression in culture [16]. To verify that the
cultures contain tumor cells, p53 staining was analyzed
as p53 is often mutated in high and intermediate grade
serous ovarian cancer [18]. A clear nuclear p53 staining
was observed in all cultures, indicating the cultures do
indeed consist of tumor cells.
We first tested whether miR-634 overexpression in pri-
mary tumor cells gave rise to a reduced viability, as was
observed for the ovarian cancer cell lines. Remarkably,
miR-634 overexpression in primary cell cultures only
mildly diminished (5–25 %) the number of viable cells
(Fig. 3a).
miR-634 overexpression gave rise to a significant and
reproducible decrease in cisplatin resistance in five cul-
tures (Fig. 3b, Additional file 1: Figure S4). Note that in
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Fig. 2 MiR-634 mimic enhances sensitivity for cisplatin in ovarian cancer cell lines. Ovarian cancer cell lines were transfected with miR-634 mimic or a
scrambled control. 48 h after transfection, cisplatin was added and after 24H cell viability was determined with an MTT assay. a Overexpression of
miR-634 miRNA in the sensitive A2780 and resistant A2780 DDP cell lines. Error bars represent the standard deviation within one
experiment (n = 5). ** = p < 0.01. b Overexpression of miR-634 miRNA in the OV56, TOV21G, OAW42, TOV112D ovarian cancer cell lines.
The cisplatin concentration is based on the IC25 value of mock transfected cells). Error bars represent the standard deviation within one
experiment (n = 3). * = p < 0.05
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cultures 1 and 2 miR-634 overexpression gave rise to a
similar phenotype, however, they could only be tested
once due to low cell numbers. When the data of all
primary cultures were combined, miR-634 overexpres-
sion was associated with a significant reduction in cellu-
lar viability of cells treated with 15 or 30 μM cisplatin
(p = 0.002, p < 0.001, respectively).
Next, we tested if miR-634 could alter the response to-
wards other anticancer compounds. miR-634 overex-
pression gave rise to significant increases in carboplatin
sensitivity in cultures 3 and 7 (Fig. 3c, Additional file 1:
Figure S5) as well as reduced resistance in two other cul-
tures (which could only be tested once). We could not
examine other cultures because of low cell numbers. In
addition, miR-634 overexpression gave rise to a signifi-
cant increase in doxorubicin sensitivity (p = 0.004),
whereas there was no significant reduction in sensitivity
for paclitaxel (p = 0.335) (Fig. 3d, e). These data indicate
that miR-634 overexpression sensitizes resistant primary
ovarian cancer cells to cisplatin, carboplatin and
doxorubicin.
MiR-634 modulates the expression of key proliferation
genes
MiRNAs mainly act by downregulating the expression of
protein-coding genes. In order to identify target genes,
we performed a pathway analysis on genes predicted to
be a miR-634 target. Among the most enriched Gene
Ontology (GO) terms were ‘positive regulation of cyclin-
dependent protein kinase activity’ and ‘regulation of the
G1-S transition of the mitotic cell cycle’ (Additional file
1: Figure S6, Table S3). Notably, Cyclin D isoforms
CCND1 and CCND2 were associated with these GO
terms, which activity is required for the G1 to S phase
transition. Overexpression of miR-634 resulted in a de-
creased CCND1 protein level in A2780, A2780 DDP and
primary tumor cells (derived from patient 3) (Fig. 4a)
and this may explain the slight increase in G1 cells at
48 h after transfection (Fig. 1a).
Another GO term that was enriched was ‘positive
regulation of proliferation’. Several proliferation
pathways were predicted to be regulated by miR-634,
most notably the Ras-MAPK pathway, of which GRB2,
N-RAS, RAF, ERK2, RSK1 and RSK2 (Additional file 1:
Table S3 and S4, Additional file 1: Figure S6) are poten-
tial targets. Concurringly, overexpression of miR-634
gave rise to reduced protein levels of GRB2, ERK2, RSK1
and RSK2 in the A2780 cell lines and primary cell cul-
ture 3 (Fig. 4b). Since miRNAs can regulate target ex-
pression by translational repression and/or mRNA
degradation, we also examined target mRNA levels.
Whereas there was only a slight decrease in CCND1
mRNA levels in miR-634 transfected cells, we observed
a 25–75 % decrease in GRB2, ERK2, RSK1 and RSK2
mRNA levels (Fig. 4c).
We next tested whether miR-634 could directly
regulate these genes. For each of the potential target
genes, luciferase constructs were generated that ex-
press part of the 3’UTR containing the miR-634 target
site (Additional file 1: Figure S7). As ERK2 and RSK2
contain respectively three and two canonical miR-634
target sites, the 3’UTR surrounding these sites was
cloned separately. As expected, miR-634 could inhibit
the 3’UTR of CCND1 and GRB2, the ERK2 3’UTR
(constructs ERK2_1 and ERK2_2) and the RSK2
3’UTR (construct RSK2_2) (Additional file 1: Figure
S8). In contrast, we observed no repression of the
miR-634 target site in the RSK1 3’UTR, suggesting
that the effect of miR-634 on RSK1 protein and
mRNA levels may be indirect.
To confirm specific binding, the miR-634 binding
site was mutated in the relevant constructs (CCND1,
GRB2, ERK2_1, ERK2_2, RSK2_2). Since construct
RSK2_2 contained two potential binding sites
(Additional file 1: Figure S7), we created one con-
struct with a mutation in the canonical site only
(RSK2_2 mut 1) and another construct with muta-
tions in both sites (RSK2_2 mut 2). As indicated in
Fig. 4d, miR-634 could no longer repress the mutated
3’UTRs of CCND1, GRB2, and ERK2. Interestingly,
mutation of both sites in RSK2_2 was necessary to
completely prevent miR-634 binding.
Table 1 Ovarian cancer patient characteristics
Histological subtype FIGO stage Grade Cytotoxic agents used Response to last Pt containing treatment
Patient 1 Serous IV 2 Carboplatin, Paclitaxel PD within 1 month
Patient 2 Serous IIIc UK Carboplatin, Paclitaxel, Gemcitabine PD within 4 months
Patient 3 Serous IIIc 3 Carboplatin, Paclitaxel, Gemcitabine PD within 1 month
Patient 4 Serous IIIc 2 Carboplatin, Paclitaxel, Olaparib, Caelyx PD during treatment
Patient 5 Clear cell IIIc 3 Carboplatin, Ifosfamide PD within 1 month
Patient 6 Serous IIIc 3 Carboplatin, Paclitaxel, Caelyx PD within 5 months
Patient 7 Serous IIIc 2 Chemotherapy naive
UK: Unknown, Pt: Platinum, PD: Progressive disease, Caelyx: liposomal doxorubicin
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Fig. 3 MiR-634 mimic enhances chemotherapy sensitivity in primary ovarian cancer cell cultures. a Overexpression of miR-634 in primary ovarian
cancer cell cultures, derived from the ascites of ovarian cancer patients, has no or a moderate effect on cell viability 72 h after transfection.
Indicated is the viability of miR-634 transfected cells relative to the viability of cells transfected with scrambled mimic (set at 100 %). The numbers
on the X-axis refer to the number of the culture. Depicted are average values ± SD (n= 3). b MiR-634 enhances the sensitivity for cisplatin. Depicted are the
results of a representative experiment for culture 3 (left, n= 4) and culture 7 (right, n= 3). An overview of the results obtained for all cultures is in Additional
file 1 Figure S4. * = p< 0.05, ** = p< 0.01. c MiR-634 enhances the sensitivity for carboplatin. Depicted are the results of a representative experiment for
culture 3 (left, n= 3) and culture 7 (right, n= 4). An overview of all cultures that were treated with carboplatin is in Additional file 1: Figure S5. * = p< 0.05,
d MiR-634 enhances the sensitivity for doxorubicin. Depicted are the results of a representative experiment for culture 3 (left, n= 3) and culture 7 (right,
n= 3). ** = p< 0.01. e MiR-634 does not significantly alter the sensitivity for paclitaxel. Depicted are the results of a representative experiment for culture 3
(left, n= 3) and culture 7 (right, n= 3)
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As an alternative approach to inhibit miR-634 function
we assessed the effect of a specific antisense inhibitor on
the luciferase activity of the wild-type 3’UTRs of miR-
634 target genes. As shown in Additional file 1: Figure
S9, inhibition of endogenous miR-634 led to increased
luciferase activity with the RSK2_2 and, to a lesser ex-
tent, GRB2 constructs, indicating that endogenous miR-
634 regulates the expression of these target genes. In this
setup we did not find an increased luciferase activity for
the ERK2 or CCND1 constructs, and therefore we can-
not confirm that ERK2 and CCND1 are endogenous
miR-634 targets in the A2780 DDP cell line. We next
examined the relation between miR-634 expression and
expression levels of its target genes in a large cohort
of ovarian serous cystadenoma’s (TCGA dataset)
(Additional file 1: Figure S10). Unfortunately, in the ma-
jority of tumors miR-634 expression was not detected
above background. However, when we examined the
b
c d
Fig. 4 MiR-634 regulates genes involved in cell cycle regulation and the Ras-MAPK pathway. Ovarian cancer cell lines (A2780, A2780 DDP) and
patient derived tumor cells (culture #3) were transiently transfected with scrambled control (-) or miR-634 mimic (+). 48 h after transfection protein
lysates were analyzed for the expression of putative miR-634 target genes by Western blotting (A, B) or RT-PCR (C). a Transfection with miR-634
reduces Cyclin D1 protein levels in the A2780 cell lines and in primary ovarian cancer cell cultures. β-actin is used as a loading control. b MiR-634
overexpression reduces protein levels of GRB2, ERK2, RSK1 and RSK2, components of the Ras-MAPK pathway in the A2780 and A2780 DDP cell
lines and primary ovarian cancer cell cultures. β-actin is used as a loading control. c MiR-634 overexpression lowers mRNA levels of CCND1, GRB2,
ERK2, RSK1 and RSK2 in the A2780 DDP cell lines 48 h after transfection. Expression was normalized to HPRT and GAPDH expression. Depicted are
average values ± SD (n = 2). The mRNA level in cells transfected with scrambled mimic is set at 100 %. d MiR-634 binds directly to elements of the
3’UTR of CCND1, GRB2, ERK2 and RSK2. A2780 DDP cells were transfected with a scrambled mimic or a miR-634 mimic. After 8 h, the same cells
were transfected with a Renilla luciferase reporter construct (psiCHECK™-2) containing a region of 500 bp surrounding the predicted target sites
(Additional file 1: Figure S7), or a luciferase construct in which the miR-634 binding sites were mutated. Since RSK2 contains both a canonical and
a non-canonical miR-634 binding site, one construct was generated that contained a mutation in the canonical binding site (RSK2_2 mut 1) and
another construct that contained mutations in both the canonical and non-canonical site (RSK2_2 mut 2). The Renilla luciferase activity was
measured and normalized using the Firefly luciferase activity. For each construct, the relative luciferase activity of cells transfected with the
scrambled mimic was set at 1. Depicted are the average values ± SD (n = 3). * p < 0.05, ** p < 0.01
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23 tumors with high miR-634 expression (expression >
mean + stdev) we found a significant negative correl-
ation between miR-634 levels and RSK2 (p = 0.002).
We also found an inverse relation between miR-634
and ERK2 (p = 0.091 or p = 0.310 for different probes),
RSK1 (p = 0.372) and GRB2 (p = 0.614), but in this set
of 23 expressing tumors this relation was not signifi-
cant. It is possible that in a larger dataset this rela-
tion becomes significant. We did not observe an
inverse relation between miR-634 and CCND1 expres-
sion in this dataset.
Altogether, our findings show that overexpression of
miR-634 leads to direct repression of RSK2, CCND1,
GRB2 and ERK2 in ovarian cancer cell lines and ovar-
ian cancer cells derived from patients. Repression of
the Ras-MAPK pathway may contribute to the de-
crease in cellular proliferation observed upon miR-634
overexpression (Fig. 1b, c, d). In line with this, we
observed that the MEK inhibitor PD0325901 reduced
cellular viability at 48H after treatment (Additional
file 1: Figure S11A). In addition, Ras-MAPK signaling
may contribute to cisplatin resistance [19]. Our previous
work has demonstrated that RSK2 depletion enhances
cisplatin sensitivity [20]. Concurringly, PD0325901
augmented cisplatin toxicity at 24H after treatment
(Additional file 1: Figure S11B).
Discussion
The aim of this study was to discover miRNAs that
affect the response of ovarian cancer cells to cisplatin
chemotherapy. We compared the expression of three
cisplatin-sensitive and –resistant cell line pairs and iden-
tified miR-634 as a miRNA that can modulate the sensi-
tivity to various drugs in ovarian cancer cells.
miR-634 is located on chromosome 17 within intron
15 of PRKCA (Protein Kinase C α), and is only con-
served in primates. miR-634 has been first detected in
colon cancer cells [21] via miRNA serial analysis of gene
expression (miRAGE). Afterwards, miR-634 has been
identified as a miRNA able to regulate the expression of
the androgen receptor (AR) in prostate cancer cells [22].
Repression of AR resulted in a reduced viability, how-
ever, the effect of miR-634 overexpression was stronger
than the effect of AR siRNA, suggesting that miR-634
may target other survival genes as well. We now report
that miR-634 overexpression results in downregulation
of multiple genes of the Ras-MAPK pathway, an import-
ant cell proliferation pathway that is activated in many
types of cancer [8].
The observation that miR-634 is able to regulate mul-
tiple Ras-MAPK pathway genes instead of one key medi-
ator is thought-provoking. Interestingly, many miRNAs
appear to synergistically regulate a set of genes that
participate in similar processes, such as the miR-17-92
cluster (regulates genes involved in growth control) [23],
let-7 (represses Ras and its downstream target HMGA2)
[24, 25] and the miR-200 family (represses the epithelial-
to-mesenchymal transition (EMT) [26–29]. MiRNAs
may thus allow cells to effectively switch off similar sig-
naling pathways in response to changing circumstances,
and this may be especially relevant for proliferative path-
ways, which activity may need to be tightly controlled.
In addition, it may be advantageous for cells to switch
off production of proteins for signaling pathways that
are not active.
Repression of oncogene activity often leads to cell
death in cancer cells, a phenomenon known as ‘onco-
gene addiction’ [30]. The reduction in cell viability
observed in the ovarian cancer cell lines upon overex-
pression of miR-634 may be caused by repression of the
Ras-MAPK pathway. Interestingly, the effects of miR-
634 overexpression in primary cultures are much less
pronounced, suggesting that these cells depend less on
proliferation signaling. In support of this theory, the as-
cites derived tumor cells divided more slowly than the
ovarian cancer cell lines, and the fastest growing cultures
(cultures 3 and 7) showed the largest reduction in cell
viability upon miR-634 overexpression.
We describe that miR-634 transfection results in en-
hanced cisplatin sensitivity. Intriguingly, this effect of
miR-634 overexpression is most apparent in resistant
ovarian cancer cell lines, and also occurs in tumor
cells derived from ascites. The miR-634 mediated re-
pression of the Ras-MAPK pathway might contribute
to the sensitization [19], which is supported by our
finding that a MEK inhibitor enhances cisplatin sensi-
tivity. Both ERK2 and RSK2 can inhibit several pro-
apoptotic genes [31–35], and as a consequence of
repression by miR-634, downregulation of ERK2 and
RSK2 might lower the threshold for apoptosis upon
treatment with cytotoxic therapy (Fig. 5). Indeed, our
previous study shows that depletion of RSK2 leads to
increased cisplatin sensitivity [20].
Because of the pivotal role of the Ras-MAPK path-
way in cell proliferation and cancer, inhibitors have
been developed that target this pathway [36]. How-
ever, the objective response rates are modest [37],
perhaps because tumors may rewire their signaling
pathways [38]. Since miR-634 can inhibit several key
proliferation factors simultaneously, acquired resist-
ance is less likely to be a problem for a miR-634
based therapy than it is for targeted agents. A next
step would be to study the effect of miR-634 overex-
pression on tumor growth and therapy response in a
genetic mouse model for ovarian cancer. However,
such a study is complicated by the fact that there is
no high grade serous mouse model for ovarian cancer
[39, 40], and miR-634 has no murine orthologue.
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Furthermore, miR-634 levels in tumors may correlate
with response to chemotherapy. Although some people
have detected miR-634 expression using miRAGE and
microarrays [22, 41], these studies do not report quanti-
tative PCR validation. In addition, we and a few others
were unable to detect endogenous miR-634 by RT-PCR
[21, 42], despite evidence that the assay is functional
(e.g. housekeepers RNU43, RNU48 were readily detected
in our samples and we could find a miR-634 signal in
mimic-transfected cells; Additional file 1: Figure S12).
However, some publications describe successful miR-634
detection in RT-PCR assays [43–45]. An explanation for
the discrepancy between studies could be that miR-634
is modified under certain cell-type specific conditions.
Of note, modifications at the 3’ end are not uncommon
for microRNAs [46, 47] and may prevent miR-634 detec-
tion by RT-PCR. Therefore, in order to monitor miR-634
levels in tumors, a specific high throughput miR-634 de-
tection tool needs to be developed.
Conclusions
In summary our data indicate that miR-634 is an import-
ant player in cisplatin-resistance. First of all, miR-634
was the only miRNA that was commonly downregulated
in three cisplatin/sensitive cell line pairs. Overexpression
of miR-634 transiently inhibited G1-S cycle progression
and enhanced apoptosis of ovarian cancer cells. Further-
more, miR-634 enhanced the chemotherapy response of
cisplatin-resistant ovarian cancer cell lines and drug re-
sistant patient-derived primary tumor cells. In addition,
we observed that miR-634 overexpression in ovarian
cancer cell lines and patient samples negatively regulates
important cell-cycle genes (CCND1) and Ras-MAPK
pathway components (GRB2, ERK2, RSK1 and RSK2).
Inhibition of the Ras-MAPK pathway resulted in in-
creased sensitivity to cisplatin, suggesting that the miR-
634-mediated repression of this pathway is responsible
for the effect of miR-634 on cisplatin resistance. In the
future, therapeutic delivery of this miRNA to drug
resistant ovarian cancer cells may help to resensitize pa-
tients to treatment.
Methods
Cell culture and reagents
The ovarian carcinoma cell line A2780, colon carcin-
oma cell line HCT8, bladder carcinoma cell line T24
and their cisplatin-resistant derivatives A2870 DDP,
HCT8 DDP, and T24 DDP10 have been described be-
fore [14, 15, 48, 49]. Resistant cell lines were rou-
tinely challenged with cisplatin. Ovarian cancer cell
lines OV56 and OAW42 were purchased from the
ECACC (Salisbury, UK) and TOV112D, TOV21G
were obtained from the ATCC (Manassas, VA, USA).
Characteristics of the ovarian cancer cells were pub-
lished in [50] and the authenticity of cell lines was
verified by STR analysis. All cell lines were cultured
in RPMI 1640 Glutamax (Invitrogen, Bleiswijk, The
Netherlands) supplemented with 10 % FBS (Greiner,
Alphen a/d Rijn, The Netherlands) and Penicillin/
Streptomycin (final concentration 100 IE each, Sigma,
Zwijndrecht, The Netherlands). Cisplatin, Carboplatin,
Paclitaxel and Doxorubicin were obtained from
Pharmachemie, Haarlem, the Netherlands. PD0325901
(cat # PZ0162) was obtained from Sigma-Aldrich.
Isolation and culture of primary ovarian tumor cell
cultures occurred as described before [16, 17]. Briefly,
25 mL ascites fluid was mixed 1:1 with MCDB105/
M199 medium supplemented with 0.5 μg/mL
Fungizone and 50 μg/mL Gentamycine (all obtained
from Sigma-Aldrich), and incubated at 37 °C, 5 %
CO2, in T75 flasks for 4 days. Afterwards, the
medium was replaced with fresh MCDB105/M199
medium and replaced twice weekly until cells were
confluent. Cells were split 1:2-1:3 for up to 6 pas-
sages. To verify that the cultures contain tumor cells,
cytospins were analyzed for epithelial markers (pan-
keratin and EpCAM) and p53.
Ras/ERK 
pathway
Proliferation
miR-634 Pt/Dox
Cell death
Cyclin D1
Cell cycle progression
Fig. 5 MiR-634 enhances the sensitivity for chemotherapy. By regulation of Cyclin D1 and the Ras-MAPK pathway, miR-634 overexpression may
affect the cell cycle profile and apoptosis. Furthermore, repression of the Ras-MAPK pathway, which inhibits several pro-apoptotic factors (e.g. Bad
[55], BimEL [56, 57]), can indirectly sensitize ovarian tumors to chemotherapeutics, such as cisplatin/carboplatin (Pt) and doxorubicin (dox)
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The study was approved by the Medical Ethical Com-
mittee of the Erasmus University MC (MEC-2008-183).
Microarray and data analysis
Total RNA was isolated with RNA Bee (BioConnect,
Huissen, the Netherlands), and 1 μg RNA was labeled
with the Cy3-TM ULS labeling kit (Kreatech Biotechnol-
ogy, Amsterdam, The Netherlands), according to the
manufacturer’s instructions. The RNA was hybridized
with the LNA-based capture probe set (Exiqon, Vedbaek,
Denmark) version 10 (annotation version 13). This
probe set consists of 1344 probes including 725 human
miRNAs, which are spotted in duplicate. Spots were
quantified with the Imagene software (BioDiscovery), ob-
vious outliers were removed and quantile normalization
was performed.
miRNA profiling experiments were performed with
RNA isolated at two (HCT8 and T24) or three
(A2780) different passages. The average miRNA ex-
pression in the sensitive cell line was compared with
the average expression in the resistant cell line and
the fold-change was calculated. The microarray
expression data has been deposited to the Gene
Expression Omnibus (GEO) data repository (accession
number GSE54665).
RT-PCR
0.5-1 μg RNA was reverse transcribed using random
primers (Applied Biosystems, Bleiswijk, The
Netherlands). 45 ng cDNA was used in a real-time PCR
reaction using Taqman® assays-on-demand (CCND1,
ERK2, GRB2, RSK1, RSK2). Expression was normalized
to HPRT and GAPDH expression using the comparative
CT-method [51]. MiRNA expression was determined
using Taqman® miRNA assays (Applied Biosystems) ac-
cording to the manufacturer’s protocol. In brief, 50 ng of
total RNA was reverse transcribed using specific miRNA
primers. The cDNA was used as input in a quantitative
real-time PCR. RNU43 and RNU48 expression were
used for normalization using the comparative CT-
method [51].
Transfection
A miRIDIAN mimic for miR-634 (C-300961-01), a
scrambled mimic (Mimic negative control #1; CN-
001000-01), a miRIDIAN hairpin inhibitor for miR-
634 (IH-300961-03), a scrambled miRIDIAN hairpin
inhibitor (negative control; IN-001005-01) and trans-
fection controls (miRIDIAN mimic with Dy547; CP-
004500-01/miRIDIAN hairpin inhibitor with Dy547;
IP-004500-01) were obtained from Dharmacon
(Epsom, UK). The seeding concentrations (cells/well)
in 24 well plates were for A2780 and A2780 DDP
4.5*104, for OV56 and TOV21G 4*104, for OAW42
3*104, for TOV112D 6*104 and for primary ovarian
cell cultures 4*104 in a final volume of 450 μL
medium without antibiotics. On the day after seeding,
50 μL of a mixture of Dharmafect 1 (final concentra-
tion 0.3 % (v/v)) and mimic (final concentration 50
nM) or inhibitor (final concentration 25 nM) in
serum-free medium was added dropwise to each well.
Under these conditions, the transfection efficiency
was over 90 % as determined using fluorescently la-
beled mimics. 48 h after transfection, drugs were
added in varying concentrations. After 24 h of con-
tinuous drug exposure, an MTT assay was performed
[52]. psiCHECK™-2 constructs were transfected using
Fugene HD (Promega) according to recommendations
by the manufacturer.
FACS analysis
Forty-eight and seventy-two hours after miRNA trans-
fection, cells were harvested and stained with FITC-
Annexin V and Propidium iodide (PI) (FITC Annexin V
Apoptosis Detection Kit I (BD Pharmingen, Breda, The
Netherlands)) or, for cell cycle analysis, fixed in 70 %
ethanol on ice, washed with PBS, then stained with PI
(20 μg/mL in PBS-0.5 mL).
Platinum measurements
Platinum measurements in cell lysates were carried out
essentially as described before using Atomic Absorption
Spectrophotometry (AAS) [53].
Cytospins and immunohistochemistry
Primary ovarian cancer cell cultures were harvested
using a cell scraper and collected in tubes, washed and
resuspended in PBS containing 1 % BSA. 50-100 μL (de-
pending on cell number) was used for cytospin prepar-
ation. Slides were air-dried for 30 min, fixed O/N in
10 % formalin, then stored in 70 % ethanol at 4 °C, until
IHC staining. IHC staining was performed using
Ventana Benchmark ULTRA automated slide stainers,
and antibodies against pan keratin (Neomarkers,
Fremont,CA, USA, MS-343-P), EpCAM (DAKO,
Heverlee, Belgium, M0804) and p53 (DAKO, M7001).
Pathway analysis
The entire list of predicted miR-634 targets in Targets-
can v6.0 (http://www.targetscan.org) was used for path-
way analysis using the analysis wizard of DAVID
Bioinformatics Resources (http://david.abcc.ncifcrf.gov/
tools.jsp). Analyzed were enriched GO-terms (BP_fat;
Additional file 1: Table S3) and enriched pathways (BIO-
CARTA, KEGG; Additional file 1: Table S4).
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Western blot analysis
Fifteen to twenty μg of total protein of each sample was
subjected to SDS-PAGE/Western blotting. Specific pro-
teins were detected with antibodies against mouse GRB2
(BD Pharmingen, 610111), mouse RSK2 (Santa Cruz,
Heerhugowaard, The Netherlands, SC-9986), rabbit
ERK1/2 (Cell signaling, Leiden, The Netherlands,
#9102), rabbit RSK1 (Santa Cruz, SC-231), rabbit
CCND1 (Thermoscientific, Etten-Leur, The Netherlands,
RM-9104-S) and mouse anti-β-actin (Sigma, A5441).
Secondary HRP-conjugated antibodies used were Goat-
anti-mouse (Santa Cruz, SC-2005) and Goat-anti-rabbit
(Jackson ImmunoResearch, Westgrove, PA, USA, 111-
035-144).
Cloning
Parts of the 3’UTR of CCND1, GRB2, ERK2, RSK1
and RSK2 (see Additional file 1: Figure S7) were PCR
amplified from human genomic DNA (Promega)
introducing a XhoI (5’-end) and a NotI site (3’-end).
The PCR products were cloned in pCR®-Blunt,
followed by XhoI and NotI restriction digests and
ligation in psiCHECK™-2 (Promega). The constructs
were verified by sequencing. The putative miR-634
target sites were mutated, forming a SmaI site to effi-
ciently screen for mutants, in the CCND1, GRB2,
ERK2 and RSK2 3’UTR constructs, using the Quick-
change site-directed mutagenesis kit (Stratagene;
Additional file 1: Figure S7).
Luciferase assay
Forty-eight hours after transfection with the miRNA
mimics/inhibitors and the psiCHECK2 constructs, a
luciferase assay (Promega; Dual-Luciferase Reporter
assay) was carried out according to the manufacturer’s
instructions. The Renilla luciferase expression was
normalized on the Firefly luciferase signal.
Statistical analysis
A paired SAM analysis [54] was performed to com-
pare miRNA expression profiles of cisplatin sensitive
and resistant ovarian (A2780/A2780 DDP), colon
(HCT8/HCT8 DDP) and bladder cancer cell lines
(T24/T24 DDP). Two-tailed paired sample T-tests
were used to assess whether differences were consist-
ent between the scrambled mimic and miR-634
(Figs. 1, 2, 4d). Two way ANOVA’s were used to
examine whether miR-634 overexpression had a sig-
nificant effect on drug sensitivity, independent of the
ascites batch. Furthermore, the effect of miR-634
overexpression on drug sensitivity in individual ascites
cultures was assessed using paired sample T-tests
(Fig. 3, Additional file 1: Figure S3 and S4). miR-634
and CCND1, ERK2, RSK1 and RSK2 expression was
examined in 535 ovarian serous cystadenoma’s (TCGA
dataset, (http://cancergenome.nih.gov/). Spearman rank
tests were used to correlate target gene expression in
tumors with high miR-634 expression (expression >mean
+ stdev) (Additional file 1: Figure S10).
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